Prevalence of Anemia and Associated Factors among Newly Diagnosed Patients with Solid Malignancy at Tikur Anbessa Specialized Hospital, Radiotherapy Center, Addis Ababa, Ethiopia
Table 2
Prevalence of anemia among associated factors in newly diagnosed solid cancers at TASH, Addis Ababa, Ethiopia, from April to May 2014 ().
Factors
No (%)
HGB range, in g/dl
Mean HGB ± SD, in g/dl
Percentage with HGB ≤ 11 g/dl
Sex
Male
144 (34.1)
4.8–18.9
13.28 ± 2.47
25 (17.4)
Female
278 (65.9)
4.6–18.7
12.18 ± 2.1
72 (25.9)
Age categories
18–34
78 (18.5)
7.8–18.4
13.43 ± 2.15
10 (12.8)
35–49
153 (36.3)
4.6–18.7
12.45 ± 2.4
40 (26.1)
50–64
135 (32.0)
5.1–18.9
12.45 ± 2.2
30 (22.2)
>65
56 (13.3)
6.2–14.8
11.89 ± 2.11
17 (30.4)
Tumor types
Gynecology
122 (28.9)
4.6–16.2
11.45 ± 2.32
46 (37.7)
Breast
96 (22.7)
8.2–16.4
12.95 ± 1.52
14 (14.6)
Colorectal
30 (7.1)
4.8–18.3
12.34 ± 2.83
8 (26.7)
NPC
32 (7.6)
8.6–16.4
12.49 ± 1.95
8 (25.0)
Sarcoma
29 (6.9)
7.2–18.4
13.09 ± 2.46
5 (17.2)
Head and neck
19 (4.5)
7.8–15.9
13.29 ± 2.29
3 (15.8)
Thyroid
14 (3.3)
10.9–15.7
13.19 ± 1.70
2 (14.3)
Hepatoma
8 (1.9)
10.5–14.7
13.16 ± 1.19
1 (12.5)
Others
72 (17.1)
4.8–18.9
13.43 ± 2.46
10 (13.9)
Tumor stages
Stage I
54 (12.8)
4.8–18.7
13.35 ± 2.35
7(13.0)
Stage II
129 (30.6)
4.8–18.3
12.53 ± 2.30
32 (24.8)
Stage III
174 (41.2)
4.6–18.9
12.15 ± 2.39
51 (29.3)
Stage IV
65 (15.4)
8.3–17.7
13.02 ± 1.66
7 (10.8)
ECOG PS
Grade 0
78 (18.5)
7.9–18.7
13.04 ± 2.09
12 (15.4)
Grade 1
154 (36.5)
6.9–18.9
12.77 ± 2.19
33 (21.4)
Grade 2
87 (20.6)
4.6–17.7
11.95 ± 2.56
26 (29.9)
Grade 3
79 (18.7)
6.2–18.4
12.17 ± 2.19
24 (30.4)
Grade 4
24 (5.7)
5.1–15.9
13.07 ± 2.32
2 (8.3)
ECOG performance score: 0 = fully active; 1 = restricted in physically strenuous activity but able to carry out light work or activities; 2 = ambulatory and capable of self-care but unable to work; 3 = capable of only limited self-care, confined to bed or chair > 50% of time; 4 = completely disabled, totally confined to bed or chair.
